Loading...
•
Mar 31, 2024
Verve Therapeutics Q1 2024 Earnings Report
Verve Therapeutics reported its Q1 2024 financial results and pipeline progress.
Key Takeaways
Verve Therapeutics reported a net loss of $48.7 million for the first quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $606.4 million, expected to fund operations into late 2026. They also achieved the first milestone payment from Eli Lilly for collaboration on an in vivo gene editing program targeting lipoprotein(a) (Lp(a)).
First patient dosed in Heart-2 Phase 1b clinical trial of VERVE-102.
VERVE-201 clinical trial initiation is on track for the second half of 2024.
Received first milestone payment from Eli Lilly for collaboration on an in vivo gene editing program targeting lipoprotein(a) (Lp(a)).
Cash, cash equivalents and marketable securities of $606.4 million; cash runway into late 2026.
Revenue by Segment
Forward Guidance
Verve expects to provide a data update on the PCSK9 program in 2025 and continues to expect its capital position to be sufficient to fund its operations into late 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...